Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

homa (CTCL) trial update and chronic lymphocytic leukemia (CLL) trial initiation

The forodesine HCl CTCL pivotal trial is enrolling as planned. This trial has been reviewed under a Special Protocol Assessment (SPA) from the United States Food & Drug Administration (FDA) to support regulatory approval.

BioCryst has also initiated a second clinical trial for patients with CLL based upon data presented at the December 2007 ASH meeting, which demonstrated the potential of forodesine HCl as a treatment for CLL, both as a single agent and in combination with bendamustine. This second CLL trial is a single-arm study evaluating single agent forodesine HCl as a treatment for patients with CLL; response rate is the primary endpoint. The first patient was dosed during the first quarter 2008, and BioCryst will provide a trial update by year end.

Intramuscular (i.m.) peramivir clinical development update

BioCryst initiated a Phase III i.m. peramivir trial early this year and voluntarily discontinued it after 82 of the planned 600 patients had enrolled because of a decision to pursue higher doses in a Phase II setting. Patients with influenza A and B were treated with either placebo or 300mg of i.m. peramivir. Although only 14% of the planned patients were enrolled in the study, results supported the activity of 300mg peramivir. The study was designed to show a difference within the influenza A subgroup, where preliminary clinical data showed a 30 hour reduction in time to alleviation of symptoms in patients that received peramivir compared to those who received placebo. Preliminary results from the overall population showed a reduction in time to alleviation of symptoms of approximately 14 hours. Because the trial was not carried out to completion, the sample size was small; the observed treatment effect was not statistically significant.

These results are consistent with data from previous clinical trials:

-- Reductions in time to
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... Foundation for Angelman Syndrome Therapeutics (FAST) announces it will ... treatment for the rare genetic disorder, Angelman Syndrome (AS).  ... study will examine if the off label administration ... with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is ...
... Feb. 14, 2012  Milo Biotechnology will receive $250,000 ... assistance and some capital into early stage Northeast ... a therapy to increase muscle strength and improve ... Milo is the 61st company in JumpStart,s portfolio. ...
... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... in the quarter grew 16%, to a new record of ... to a new high of $0.72. "Gen-Probe finished ... quarter while clinical diagnostics revenues continued their solid growth," said ...
Cached Biology Technology:Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 2Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 3JumpStart Invests $250,000 in Milo Biotechnology 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
(Date:7/30/2014)... of cells types. Researchers would like to understand how to ... that make up the organs and other structures of living ... of sugars that dangle from proteins on surfaces of cells. ... Diego, has created synthetic molecules that can stand in for ... direct the process, they report in the Journal of ...
(Date:7/29/2014)... New research by academics in the University of Bristol,s ... we take liquid calories into account when planning meals. ... for the Study of Ingestive Behavior Conference (SSIB 2014) ... August], argues that we do. , The team was ... the School of Experimental Psychology. , As part of ...
(Date:7/29/2014)... Research and Markets  has announced the addition of ... report to their offering. ... refers to applications and technologies that are used for ... company,s operations. BI help organizations to acquire comprehensive knowledge ... on sales, production, and internal operations. ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... membranes could help phytoplankton cope with nutrient scarcity in the ... of the National Oceanography Centre has shown that a species ... of its cell membranes in response to changes in nutrient ... for nutrient cycling and the population dynamics of phytoplankton in ...
... JUPITER, FL, December 16, 2010 Scientists from ... shown that prions, bits of infectious protein that can ... (BSE) or "mad cow disease," have the ability to ... In this regard, although they lack DNA and RNA, ...
... Researchers funded by the Biotechnology and Biological Sciences Research ... clue that may help to explain why the earliest evidence ... ago, when atmospheric oxygen levels on the planet rose sharply ... The team, led by Professor Chris Schofield, has found that ...
Cached Biology News:Efficient phosphorus use by phytoplankton 2Scripps Research scientists show prions mutate and adapt to host environment 2Scripps Research scientists show prions mutate and adapt to host environment 3550 million years ago rise in oxygen drove evolution of animal life 2
Automated Cell Culture Flask...
... system, 100-240 V, is an optional module ... automates delivery of up to 20 L ... reader. The HTF system automatically draws sheath ... to constantly maintain a reservoir of pressurized ...
... every research laboratory, the revolutionary Luminex 100 ... inexpensively and in real time enhancing your ... system includes the Luminex 100, the XY ... technology which enables you to simultaneously assay ...
... routine binary separations. Excellent detection is provided ... variable wavelength detector. Ultra-fine control of the ... highly accurate and precise, high pressure dual piston ... may be plotted on a printer or an ...
Biology Products: